# GCC Keytruda Market > GCC Keytruda Market Research Report By Cancer Type (Melanoma, Lung cancer, Hodgkin lymphoma, Stomach cancer, Urothelial carcinoma) and By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.21% - **2024:** $ 880.33 Million - **2025:** $ 961.41 Million - **2035:** $ 2,319 Million - **Key Players:** Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US) **Report ID:** MRFR/HC/43644-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-keytruda-market-45324 --- ## Market Summary ## **GCC Keytruda Market Overview** As per MRFR analysis, the GCC Keytruda Market Size was estimated at 744.23 (USD Million) in 2024The GCC Keytruda Market Industry is expected to grow from 812.7(USD Million) in 2025 to 3,270.0 (USD Million) by 2035. The GCC Keytruda Market CAGR (growth rate) is expected to be around 13.492% during the forecast period (2025 - 2035). **Key GCC Keytruda Market Trends Highlighted** The GCC Keytruda market is witnessing significant growth driven by various factors, notably the increasing incidence of cancer and an evolving healthcare landscape in the region. Key market drivers include government initiatives aimed at improving cancer care, increased investment in healthcare infrastructure, and a rising emphasis on innovative treatment options. The GCC governments are actively investing in healthcare systems, encouraging local production and enhancing access to advanced therapies like Keytruda, particularly in countries such as Saudi Arabia and the UAE. Opportunities to be explored in the GCC Keytruda market include expanding clinical trials, collaborations between pharmaceutical companies and local healthcare providers, and enhancing patient education programs on immunotherapy. There is also a notable shift towards personalized medicine, creating a conducive environment for the adoption of targeted therapies. In recent times, trends indicate a greater acceptance of immunotherapy as a first-line treatment option for various cancers. Awareness campaigns promoting early detection and treatment have increased, further accelerating market growth. Furthermore, collaborations with research institutions are leading to breakthroughs in understanding cancer biology, which could enhance the efficacy of Keytruda in treating diverse oncological conditions. As the region continues to support regulatory frameworks that facilitate faster approval processes for new drugs, the Keytruda market in the GCC is likely to thrive.Overall, the combination of rising cancer prevalence, supportive government policies, and technological advancements positions the GCC Keytruda market as a dynamic and promising sector in the regional healthcare landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Keytruda Market Drivers** Increasing Incidence of Cancer in GCC Region The GCC Keytruda Market Industry is experiencing growth due to a significant rise in cancer incidences across the GCC region. According to research conducted by regional health ministries, cancer rates in countries like Saudi Arabia have increased by approximately 15% over the last decade. This surge is attributed to lifestyle changes, urbanization, and an aging population. The Saudi Arabian Ministry of Health has reported that nearly 50,000 new cancer cases were diagnosed in 2020 alone, further emphasizing the urgent need for advanced treatments like Keytruda.This growing patient demographic is driving demand for immunotherapy options, thus propelling the Keytruda market forward. Major oncology hospitals and organizations in the GCC are increasingly adopting immunotherapy as a leading treatment method, which further supports the favorable growth trend in this sector. Government Initiatives and Healthcare Investment In the GCC, governments are taking substantial steps to enhance healthcare infrastructure and promote innovative treatment options, including immunotherapies. Countries like the UAE and Qatar have increased their healthcare budgets, focusing on cutting-edge treatments integral to tackling cancer effectively. For instance, the UAE Vision 2021 aims for a world-class healthcare system, resulting in a 12% yearly increase in healthcare spending. These initiatives not only boost accessibility but also stimulate the local Keytruda market as healthcare providers expand their oncology treatment capabilities amid rising cancer cases.The engagement of public institutions in supporting advanced therapies aligns with Keytruda's market growth prospects within the region. Rising Adoption of Personalized Medicine The shift toward personalized medicine in oncology is a key driver for the GCC Keytruda Market Industry. Enhanced understanding of genetic markers and tumor profiles has led to more targeted therapies, increasing the appeal of immunotherapy drugs like Keytruda. Hospitals across the GCC have begun incorporating genomic testing in routine cancer care, with studies indicating that about 30% of new cancer treatments this year will be personalized. This trend is supported by various healthcare initiatives, with associations such as the Gulf Cooperation Council's MedTech forum advocating for investments in personalized healthcare.As more patients become eligible for Keytruda due to genetic markers, a significant expansion in the market is anticipated. **GCC Keytruda Market Segment Insights** **Keytruda Market Cancer Type Insights** The GCC Keytruda Market is experiencing notable growth in the Cancer Type segment, reflecting a significant evolution in oncology treatment paradigms across the region. The landscape demonstrates an increasing prevalence of various cancer types, leading to greater demand for innovative therapies, such as Keytruda, a PD-1 inhibitor. Among the cancer types treated with Keytruda, melanoma has gained immense traction due to its aggressive nature and high incidence rates, necessitating effective treatment options for favorable outcomes. The lung cancer segment also stands out, primarily driven by rising tobacco use and air quality concerns within the GCC region, highlighting the urgent need for advanced treatment modalities. Hodgkin lymphoma continues to be another pivotal focus, particularly given the advancements in immuneoncology, which have resulted in tailored therapies that significantly improve survival rates. Stomach cancer remains a major challenge in the GCC due to dietary habits prevalent in the region, calling for more effective management strategies and therapeutic solutions. Urothelial carcinoma, associated closely with risk factors like smoking and occupational exposure, has seen a steady rise in case numbers, making it imperative for healthcare stakeholders to invest in targeted therapies for better care pathways.The GCC Keytruda Market segmentation showcases not only the rising incidence of these cancers but also the underlying growth trends tied to public health awareness, advancements in oncology, and the increasing accessibility of innovative treatments, which together form a comprehensive response to the cancer burden in the region.  Keytruda's unique mode of action in harnessing the body’s immune response positions it favorably in this market, as stakeholders focus on improving patient outcomes across various types of cancers through continued investment and research within these crucial segments.Overall, the significance of these cancer types within the GCC Keytruda Market demonstrates both growth opportunities and challenges as the healthcare industry adapts to the evolving needs of cancer treatment in response to shifting demographics and disease prevalence. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Keytruda Market Distribution Channel Insights** The GCC Keytruda Market is experiencing notable growth within the Distribution Channel segment, comprising primarily of Hospital Pharmacies and Specialty Pharmacies. Hospital Pharmacies play a critical role in ensuring the timely and efficient delivery of Keytruda, emphasizing patient safety and medication management within healthcare settings. This channel is characterized by high demand owing to the increasing number of cancer patients receiving treatment in hospitals across GCC countries, driven by expanding healthcare infrastructure and rising awareness of immunotherapy benefits.Specialty Pharmacies, on the other hand, cater specifically to patients requiring complex and high-cost medications, like Keytruda, offering expertise in managing these therapies.  These pharmacies often provide comprehensive patient support services, including education on drug information and management of adverse effects, which significantly enhances treatment outcomes. Both channels are essential in addressing the growing need for advanced cancer therapies in the region, with the GCC experiencing a surge in cancer cases and an increasing reliance on innovative treatment options.Overall, the dynamics of pricing, reimbursement policies, and regulatory factors are crucial for shaping the future landscape of the GCC Keytruda Market within these channels. **GCC Keytruda Market Key Players and Competitive Insights** The competitive landscape of the GCC Keytruda market reveals a dynamic interplay of various pharmaceutical companies striving to establish a strong foothold in the immunotherapy sector, particularly focused on oncology treatments. Keytruda, a renowned drug known for its efficacy in treating certain types of cancers, has attracted significant interest within the region. The GCC countries represent a unique market characterized by a growing demand for advanced cancer treatments, underpinned by increasing healthcare investments and an escalating prevalence of cancer cases. Given these factors, companies are leveraging innovative strategies such as collaborations and localized production to enhance their market positions.  As the market evolves, understanding the competitive dynamics, regulatory environment, and consumer preferences becomes crucial for stakeholders seeking to capitalize on opportunities and address challenges in the GCC Keytruda market.AbbVie stands out in the GCC Keytruda market due to its strong reputation in oncology and immunology, enhanced by a robust pipeline of innovative treatments and a commitment to addressing the diverse needs of patients. The company has positioned itself effectively by leveraging its research and development capabilities, allowing it to introduce next-generation therapies that complement the relevance of Keytruda in cancer treatment. Furthermore, AbbVie's strategic collaborations with local healthcare providers and institutions have facilitated an increase in market penetration within the GCC region.  Their strong emphasis on patient-centric initiatives and educational programs has also played a vital role in building brand loyalty and trust among both healthcare professionals and patients. This holistic approach has fortified AbbVie's standing in the competitive landscape, showcasing its strengths in responding to regional healthcare demands efficiently.Biogen has also marked its presence in the GCC Keytruda market through its focus on innovation and commitment to advancing specialized therapies. Biogen is primarily recognized for its advancements in neurological treatments and has begun to diversify its portfolio to include oncology, specifically aligning its offerings with demands for immune-oncology therapies like Keytruda. The company is making strides by engaging in partnerships and collaborations that enhance its research capabilities and facilitate market entry for its products in the GCC.  Furthermore, Biogen's strengths lie in its strong emphasis on research and development, allowing it to explore novel treatment avenues that could complement existing cancer therapies. The company is actively pursuing potential mergers and acquisitions to enhance its market presence and competitiveness within the GCC, indicating its strategy of consolidating resources to maximize the impact of its product offerings. Biogen's established reputation for innovation and commitment to improving patient outcomes significantly contributes to its growing influence in the GCC Keytruda market. **Key Companies in the GCC Keytruda Market Include** **GCC Keytruda Market Industry Developments** Recent developments in the GCC Keytruda market indicate a steady growth in demand for immunotherapy treatments, with Keytruda being a significant focus. In August 2023, Merck & Co. announced an expansion of its partnership with healthcare providers in the UAE to enhance patient access to Keytruda, particularly in oncology. Additionally, in April 2023, AstraZeneca made notable strides by launching its newer oncology product in the GCC, leading to increased competition with Keytruda in the treatment of lung cancer. Furthermore, in May 2023, Bristol Myers Squibb's collaboration with local health authorities in Qatar emphasized innovative cancer treatment , indicating a robust interest in expanding immunotherapy options. Over the last two years, particularly noted in March 2022, several GCC countries, including Saudi Arabia and Kuwait, have reported significant budget allocations to enhance cancer care services, supporting the market growth for Keytruda. While there have been discussions surrounding mergers and acquisitions among top players like Gilead Sciences and Sanofi, no recent publicly known transactions have been reported in this specific sector, keeping the market landscape competitive and diversified. **GCC Keytruda Market Segmentation Insights** **Keytruda Market****Cancer Type****Outlook** **Keytruda Market****Distribution Channel****Outlook** ## Market Drivers ### Increasing Awareness of Immunotherapy The rising awareness of immunotherapy as a viable treatment option for various cancers is a crucial driver in the keytruda market. Educational campaigns and outreach programs by healthcare providers and pharmaceutical companies have contributed to a better understanding of the benefits of immunotherapy. This increased awareness is likely to lead to higher patient demand for keytruda, as more individuals seek advanced treatment options. In the GCC, the market for immunotherapy is projected to grow at a CAGR of approximately 15% over the next five years, indicating a robust interest in innovative cancer therapies. As patients become more informed about their treatment choices, the keytruda market is expected to expand significantly, driven by this heightened awareness. ### Rising Incidence of Targetable Cancers The rising incidence of targetable cancers, such as melanoma and non-small cell lung cancer, is a significant driver for the keytruda market. As the prevalence of these cancers increases in the GCC, the demand for effective treatment options like keytruda is likely to rise correspondingly. Recent statistics indicate that the incidence of melanoma has increased by 25% in the region over the last five years. This trend suggests a growing patient population that may benefit from immunotherapy. Consequently, pharmaceutical companies are focusing their efforts on expanding the availability of keytruda, anticipating a surge in demand driven by the increasing number of patients diagnosed with targetable cancers. ### Government Initiatives for Cancer Treatment Government initiatives aimed at improving cancer treatment accessibility play a pivotal role in shaping the keytruda market. In the GCC, various health ministries are implementing policies to subsidize cancer treatments, including immunotherapies like keytruda. These initiatives are designed to alleviate the financial burden on patients and ensure that cutting-edge therapies are available to a broader population. For instance, recent reports indicate that government spending on cancer care in the region has increased by over 20% in the past two years. Such financial support not only enhances patient access but also stimulates market growth, as more healthcare facilities adopt keytruda as a standard treatment option. ### Technological Advancements in Cancer Diagnostics Technological advancements in cancer diagnostics are significantly influencing the keytruda market. Innovations such as next-generation sequencing and liquid biopsies enable earlier and more accurate cancer detection, which is essential for effective treatment planning. As diagnostic technologies improve, healthcare providers in the GCC are increasingly identifying patients who are likely to benefit from keytruda. This trend is expected to enhance patient outcomes and drive demand for the drug. The integration of advanced diagnostic tools is projected to increase the number of patients eligible for immunotherapy by approximately 30% in the coming years, thereby expanding the keytruda market. ### Collaborations Between Pharmaceutical Companies and Healthcare Providers Collaborations between pharmaceutical companies and healthcare providers are emerging as a vital driver in the keytruda market. These partnerships facilitate the sharing of knowledge, resources, and clinical data, which can enhance the understanding of keytruda's efficacy and safety. In the GCC, several initiatives have been launched to promote clinical trials and research collaborations, aimed at optimizing treatment protocols for keytruda. Such collaborations are expected to lead to improved patient outcomes and increased adoption of the drug. Furthermore, as more healthcare providers gain access to the latest research findings, the likelihood of integrating keytruda into standard treatment regimens is anticipated to rise, thereby bolstering the market. ## Future Outlook The [Keytruda Market](https://www.marketresearchfuture.com/reports/keytruda-market-19207) is projected to grow at a 9.21% CAGR from 2025 to 2035, driven by increasing cancer prevalence, advancements in immunotherapy, and expanding healthcare access. **New opportunities:** - Development of personalized treatment plans leveraging genetic profiling. - Expansion into emerging markets through strategic partnerships. - Investment in digital health technologies for patient monitoring and engagement. By 2035, the keytruda market is expected to achieve substantial growth and enhanced market presence. ## Segment Insights ### By Cancer Type: Melanoma (Largest) vs. Lung Cancer (Fastest-Growing) In the GCC keytruda market, Melanoma represents the largest segment due to its high prevalence and the growing awareness of early detection methods. This segment's dominant position is supported by extensive clinical studies and favorable treatment protocols that have substantially improved patient outcomes. Meanwhile, Lung Cancer has emerged as a significant area of focus, both in research funding and treatment innovation, indicating its importance in the overall market share dynamics. The growth trends in the Cancer Type segment are primarily driven by advancements in immunotherapy, increasing healthcare expenditure, and greater access to treatments. Rising incidences of Lung Cancer, particularly due to lifestyle factors, contribute to its rapid growth, attracting significant investments and fostering competitive product development. As therapies like Keytruda gain traction, the market is expected to evolve, with both segments showing promising trajectories. Melanoma (Dominant) vs. Lung Cancer (Emerging) Melanoma continues to hold the dominant position within the GCC keytruda market, owing to its established treatment protocols and a strong patient advocacy network. The segment benefits from comprehensive clinical evidence supporting the efficacy of Keytruda, leading to high treatment adoption rates. On the other hand, Lung Cancer is positioned as an emerging focal point, with numerous ongoing clinical trials exploring novel combination therapies. The increasing prevalence of Lung Cancer in the region, combined with rising public health initiatives, enhances its visibility and growth potential, making it a critical area for future investments and innovations. ### By Distribution Channel: Hospital Pharmacies (Largest) vs. Specialty Pharmacies (Fastest-Growing) In the GCC keytruda market, Hospital Pharmacies dominate the distribution channel segment, commanding a significant share due to their established networks and ability to provide comprehensive patient care. Specialty Pharmacies, however, are rapidly gaining traction, driven by their specialization in managing complex therapies and personalized medication management. This shift indicates a diversification in customer preference towards more tailored healthcare solutions. The growth trends within this segment are fueled by an increasing demand for specialized treatments and improved patient outreach programs. Hospital Pharmacies continue to thrive due to their integral role within healthcare systems, while Specialty Pharmacies are emerging as a vital player, addressing unique patient needs and fostering innovation in drug distribution methods. The rise of chronic diseases and the demand for advanced treatments are pivotal drivers in this dynamic market landscape. Hospital Pharmacies (Dominant) vs. Specialty Pharmacies (Emerging) Hospital Pharmacies hold a dominant position in the GCC keytruda market thanks to their integrated healthcare delivery systems, providing essential services directly within hospital settings. Their role ensures that patients receive timely access to keytruda treatments as part of an overall care plan, supported by clinical teams. In contrast, Specialty Pharmacies are acknowledged as emerging players, focusing on niche markets with personalized service and specialized knowledge of keytruda and similar therapies. This has positioned them uniquely to cater to patients with specific needs, offering more individualized care pathways. As both segments evolve, they reflect the changing dynamics in patient care preferences, with Hospital Pharmacies emphasizing broad access and Specialty Pharmacies enhancing treatment personalization. ### Keytruda Market Distribution Channel Insights Keytruda Market Distribution Channel Insights The GCC Keytruda Market is experiencing notable growth within the Distribution Channel segment, comprising primarily of Hospital Pharmacies and Specialty Pharmacies. Hospital Pharmacies play a critical role in ensuring the timely and efficient delivery of Keytruda, emphasizing patient safety and medication management within healthcare settings. This channel is characterized by high demand owing to the increasing number of cancer patients receiving treatment in hospitals across GCC countries, driven by expanding healthcare infrastructure and rising awareness of immunotherapy benefits.Specialty Pharmacies, on the other hand, cater specifically to patients requiring complex and high-cost medications, like Keytruda, offering expertise in managing these therapies.  These pharmacies often provide comprehensive patient support services, including education on drug information and management of adverse effects, which significantly enhances treatment outcomes. Both channels are essential in addressing the growing need for advanced cancer therapies in the region, with the GCC experiencing a surge in cancer cases and an increasing reliance on innovative treatment options.Overall, the dynamics of pricing, reimbursement policies, and regulatory factors are crucial for shaping the future landscape of the GCC Keytruda Market within these channels. ## Competitive Benchmarking The competitive dynamics within the keytruda market exhibit a landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Merck & Co (US), Bristol-Myers Squibb (US), and Roche Holding AG (CH) are at the forefront, each leveraging distinct strategies to enhance their market presence. Merck & Co (US) continues to focus on expanding its immunotherapy portfolio, while Bristol-Myers Squibb (US) emphasizes strategic partnerships to bolster its research capabilities. Roche Holding AG (CH) is investing heavily in digital health solutions, indicating a shift towards integrating technology with traditional therapeutic approaches. Collectively, these strategies not only enhance their competitive positioning but also contribute to a dynamic market environment that is increasingly driven by innovation and collaboration.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the keytruda market appears moderately fragmented, with several players vying for market share. However, the influence of major companies remains substantial, as they set industry standards and drive advancements in treatment options. In October Merck & Co (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation immunotherapies. This collaboration is poised to enhance Merck's research capabilities and accelerate the development of innovative treatment options, thereby reinforcing its leadership position in the market. The strategic importance of this partnership lies in its potential to expand Merck's therapeutic offerings and improve patient outcomes through cutting-edge solutions. In September Bristol-Myers Squibb (US) launched a new initiative aimed at increasing access to its therapies in underserved regions of the GCC. This initiative not only reflects the company's commitment to corporate social responsibility but also positions it favorably in a market that increasingly values equitable healthcare access. By addressing disparities in treatment availability, Bristol-Myers Squibb (US) enhances its brand reputation and fosters loyalty among healthcare providers and patients alike. In August Roche Holding AG (CH) unveiled a digital health platform designed to integrate patient data with treatment protocols for keytruda therapies. This platform aims to streamline patient management and improve treatment adherence, showcasing Roche's commitment to leveraging technology in healthcare. The strategic significance of this development lies in its potential to enhance patient outcomes and optimize the therapeutic journey, thereby solidifying Roche's competitive edge in the market. As of November current trends in the keytruda market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive landscape is shifting from a focus on price-based competition to one that prioritizes technological advancements, innovative solutions, and reliable supply chains. This evolution suggests that future differentiation will hinge on the ability to deliver superior patient outcomes through cutting-edge therapies and integrated healthcare solutions. ## Recent News & Developments Recent developments in the GCC Keytruda Market indicate a steady growth in demand for immunotherapy treatments, with Keytruda being a significant focus. In August 2023, Merck & Co. announced an expansion of its partnership with healthcare providers in the UAE to enhance patient access to Keytruda, particularly in oncology. Additionally, in April 2023, AstraZeneca made notable strides by launching its newer oncology product in the GCC, leading to increased competition with Keytruda in the treatment of lung cancer. Furthermore, in May 2023, Bristol Myers Squibb's collaboration with local health authorities in Qatar emphasized innovative cancer treatment , indicating a robust interest in expanding immunotherapy options. Over the last two years, particularly noted in March 2022, several GCC countries, including Saudi Arabia and Kuwait, have reported significant budget allocations to enhance cancer care services, supporting the market growth for Keytruda. While there have been discussions surrounding mergers and acquisitions among top players like Gilead Sciences and Sanofi, no recent publicly known transactions have been reported in this specific sector, keeping the market landscape competitive and diversified. ## Report Scope | MARKET SIZE 2024 | 880.33(USD Million) | | --- | --- | | MARKET SIZE 2025 | 961.41(USD Million) | | MARKET SIZE 2035 | 2319.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.21% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US) | | Segments Covered | Cancer Type, Distribution Channel | | Key Market Opportunities | Emerging immunotherapy advancements and regulatory support enhance growth potential in the keytruda market. | | Key Market Dynamics | Rising demand for immunotherapy in the GCC region drives competitive dynamics in the Keytruda market. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the overall market valuation of the GCC keytruda market in 2024?** A: The overall market valuation was $880.33 Million in 2024. **Q: What is the projected market valuation for the GCC keytruda market by 2035?** A: The projected valuation for 2035 is $2319.0 Million. **Q: What is the expected CAGR for the GCC keytruda market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 9.21%. **Q: Which cancer types are included in the GCC keytruda market segments?** A: The cancer types include Melanoma, Lung cancer, Hodgkin lymphoma, Stomach cancer, and Urothelial carcinoma. **Q: What were the market values for Lung cancer in 2024?** A: The market value for Lung cancer was $352.13 Million in 2024. **Q: How much is the market for Hospital Pharmacies valued in 2024?** A: The market for Hospital Pharmacies was valued at $440.33 Million in 2024. **Q: What is the projected market value for Urothelial carcinoma by 2035?** A: The projected market value for Urothelial carcinoma by 2035 is $462.1 Million. **Q: Which companies are the key players in the GCC keytruda market?** A: Key players include Merck & Co, Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Novartis AG, Pfizer Inc, Eli Lilly and Company, and Amgen Inc. **Q: What was the market value for Specialty Pharmacies in 2024?** A: The market value for Specialty Pharmacies was $440.0 Million in 2024. **Q: What are the projected market trends for Hodgkin lymphoma from 2025 to 2035?** A: The market for Hodgkin lymphoma is projected to grow from $132.07 Million in 2024 to $345.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-keytruda-market-45324*